微生物叢の世界市場

◆英語タイトル:Global Microbiomes MARKET 2020-2024
◆商品コード:IRTNTR41199
◆発行会社(リサーチ会社):Technavio
◆発行日:2020年2月12日
◆ページ数:100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Global Microbiomes Market 2020-2024Technavio has been monitoring the global microbiomes market and it is poised to grow by USD 544.72 mn during 2020-2024, progressing at a CAGR of 30% during the forecast period. Our reports on global microbiomes market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of diseases.In addition, growing focus on developing biosensors and genetic circuits is anticipated to boost the growth of the global microbiomes market as well.
Market Segmentation
Technavio’s global microbiomes market is segmented as below:
Application:
o Therapeutics

o Diagnostics

Geographic Segmentation:
o Asia

o Europe

o North America

o ROW

Key Trends for global microbiomes market growth
This study identifies growing focus on developing biosensors and genetic circuits as the prime reasons driving the global microbiomes market growth during the next few years.
Prominent vendors in global microbiomes market
We provide a detailed analysis of around 25 vendors operating in the global microbiomes market, including some of the vendors such as 4D pharma Plc, ENTEROME SA, Evelo Biosciences Inc., Ferring International Center SA, Osel Inc., Second Genome Inc., Seres Therapeutics Inc., Synlogic Inc., Synthetic Biologics Inc. and Vedanta Biosciences Inc. .
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit - https://www.technavio.com/report/global-microbiomes-market-industry-analysis

About Technavio
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

【レポートの目次】

• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2019
o Market outlook: Forecast for 2019 – 2024
• Five Forces Analysis
o Five Forces Summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Application
o Market segments
o Comparison by Application placement
o Therapeutics – Market size and forecast 2019-2024
o Diagnostics – Market size and forecast 2019-2024
o Market opportunity by Application
• Customer landscape
o Overview
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America – Market size and forecast 2019-2024
o Europe – Market size and forecast 2019-2024
o Asia – Market size and forecast 2019-2024
o ROW – Market size and forecast 2019-2024
o Key leading countries
o Market opportunity by geography
• Drivers, Challenges, and Trends
o Market drivers
o Volume driver – Demand led growth
o Volume driver – Supply led growth
o Volume driver – External factors
o Volume driver – Demand shift in adjacent markets
o Price driver – Inflation
o Price driver – Shift from lower to higher priced units
o Market challenges
o Market trends
• Vendor Landscape
o Overview
o Vendor landscape
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o 4D pharma Plc
o ENTEROME SA
o Evelo Biosciences Inc.
o Ferring International Center SA
o Osel Inc.
o Second Genome Inc.
o Seres Therapeutics Inc.
o Synlogic Inc.
o Synthetic Biologics Inc.
o Vedanta Biosciences Inc.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations
• Exhibits
• 1.Key Finding 1
• 2.Key Finding 2
• 3.Key Finding 3
• 4.Key Finding 4
• 5.Key Finding 5
• 6.Key Finding 6
• 7.Key Finding 7
• 8.Market in focus
• 9.Parent market
• 10.Market characteristics
• 11.Product / Service portfolio of key vendors included in the market definition
• 12.Market segments
• 13.Global – Market size and forecast 2019 – 2024 ($ million)
• 14.Global market: Year-over-year growth 2019 – 2024 (%)
• 15.Five forces analysis 2019 & 2024
• 16.Bargaining power of buyers
• 17.Bargaining power of suppliers
• 18.Threat of new entrants
• 19.Threat of substitutes
• 20.Threat of rivalry
• 21.Market condition – Five forces 2019
• 22.Application placement – Market share 2019-2024 (%)
• 23.Comparison by Application placement
• 24.Therapeutics – Market size and forecast 2019-2024 ($ million)
• 25.Therapeutics – Year-over-year growth 2019-2024 (%)
• 26.Diagnostics – Market size and forecast 2019-2024 ($ million)
• 27.Diagnostics – Year-over-year growth 2019-2024 (%)
• 28. Market opportunity by Application
• 29.Customer landscape
• 30.Market share by geography 2019-2024 (%)
• 31.Geographic comparison
• 32.North America – Market size and forecast 2019-2024 ($ million)
• 33.North America – Year-over-year growth 2019-2024 (%)
• 34.Europe – Market size and forecast 2019-2024 ($ million)
• 35.Europe – Year-over-year growth 2019-2024 (%)
• 36.Asia – Market size and forecast 2019-2024 ($ million)
• 37.Asia – Year-over-year growth 2019-2024 (%)
• 38.ROW – Market size and forecast 2019-2024 ($ million)
• 39.ROW – Year-over-year growth 2019-2024 (%)
• 40.Key leading countries
• 41.Market opportunity by geography ($ million)
• 42.Impact of drivers
• 43.Impact of challenges
• 44.Landscape disruption
• 45.Industry risks
• 46.Vendors covered
• 47.Market positioning of vendors
• 48.4D pharma Plc – Overview (1/3)
• 49.4D pharma Plc – Overview (2/3)
• 50.4D pharma Plc – Overview (3/3)
• 51.4D pharma Plc – Business segments
• 52.4D pharma Plc – Key offerings
• 53.4D pharma Plc – Key customers
• 54.4D pharma Plc – Segment focus
• 55.ENTEROME SA – Overview (1/3)
• 56.ENTEROME SA – Overview (2/3)
• 57.ENTEROME SA – Overview (3/3)
• 58.ENTEROME SA – Product and service
• 59.ENTEROME SA – Key offerings
• 60.ENTEROME SA – Key customers
• 61.ENTEROME SA – Segment focus
• 62.Evelo Biosciences Inc. – Overview (1/3)
• 63.Evelo Biosciences Inc. – Overview (2/3)
• 64.Evelo Biosciences Inc. – Overview (3/3)
• 65.Evelo Biosciences Inc. – Business segments
• 66.Evelo Biosciences Inc. – Key offerings
• 67.Evelo Biosciences Inc. – Key customers
• 68.Evelo Biosciences Inc. – Segment focus
• 69.Ferring International Center SA – Overview (1/3)
• 70.Ferring International Center SA – Overview (2/3)
• 71.Ferring International Center SA – Overview (3/3)
• 72.Ferring International Center SA – Product and service
• 73.Ferring International Center SA – Key offerings
• 74.Ferring International Center SA – Key customers
• 75.Ferring International Center SA – Segment focus
• 76.Osel Inc. – Overview (1/3)
• 77.Osel Inc. – Overview (2/3)
• 78.Osel Inc. – Overview (3/3)
• 79.Osel Inc. – Product and service
• 80.Osel Inc. – Key offerings
• 81.Osel Inc. – Key customers
• 82.Osel Inc. – Segment focus
• 83.Second Genome Inc. – Overview (1/3)
• 84.Second Genome Inc. – Overview (2/3)
• 85.Second Genome Inc. – Overview (3/3)
• 86.Second Genome Inc. – Product and service
• 87.Second Genome Inc. – Key offerings
• 88.Second Genome Inc. – Key customers
• 89.Second Genome Inc. – Segment focus
• 90.Seres Therapeutics Inc. – Overview (1/3)
• 91.Seres Therapeutics Inc. – Overview (2/3)
• 92.Seres Therapeutics Inc. – Overview (3/3)
• 93.Seres Therapeutics Inc. – Business segments
• 94.Seres Therapeutics Inc. – Key offerings
• 95.Seres Therapeutics Inc. – Key customers
• 96.Seres Therapeutics Inc. – Segment focus
• 97.Synlogic Inc. – Overview (1/3)
• 98.Synlogic Inc. – Overview (2/3)
• 99.Synlogic Inc. – Overview (3/3)
• 100.Synlogic Inc. – Business segments
• 101.Synlogic Inc. – Key offerings
• 102.Synlogic Inc. – Key customers
• 103.Synlogic Inc. – Segment focus
• 104.Synthetic Biologics Inc. – Overview (1/3)
• 105.Synthetic Biologics Inc. – Overview (2/3)
• 106.Synthetic Biologics Inc. – Overview (3/3)
• 107.Synthetic Biologics Inc. – Product and service
• 108.Synthetic Biologics Inc. – Key offerings
• 109.Synthetic Biologics Inc. – Key customers
• 110.Synthetic Biologics Inc. – Segment focus
• 111.Vedanta Biosciences Inc. – Overview (1/3)
• 112.Vedanta Biosciences Inc. – Overview (2/3)
• 113.Vedanta Biosciences Inc. – Overview (3/3)
• 114.Vedanta Biosciences Inc. – Product and service
• 115.Vedanta Biosciences Inc. – Key offerings
• 116.Vedanta Biosciences Inc. – Key customers
• 117.Vedanta Biosciences Inc. – Segment focus
• 118.Currency conversion rates for US$
• 119.Research Methodology
• 120.Validation techniques employed for market sizing
• 121.Information sources
• 122.List of abbreviations



【掲載企業】

4D pharma Plc,ENTEROME SA,Evelo Biosciences Inc.,Ferring International Center SA,Osel Inc.,Second Genome Inc.,Seres Therapeutics Inc.,Synlogic Inc.,Synthetic Biologics Inc.,Vedanta Biosciences Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[微生物叢の世界市場]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆